{
  "docId": "019de514-4d4c-7369-a2bf-f736423e3911",
  "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53",
  "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides",
  "authorId": "imara",
  "authorName": "Enliven Therapeutics / Imara",
  "documentKindSlug": "press-release",
  "documentKindLabel": "Press release",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 45,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide uses a split-screen layout to contrast clinical challenges with the rationale for treatment switching.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/20",
  "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911",
  "deckJsonHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911.json",
  "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Majority of HCPs (77%) indicated need for more effective, safe, and tolerable agents in CML",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b881cd18-43bb-44af-ac98-4473b377a57d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.55,
        "y": 0.75
      },
      "kind": "callout",
      "text": "In the US and EU3, majority of treatment switches across lines of therapy and TKIs are driven by intolerance or initial lack of molecular response (~60% combined)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d121dc6a-b032-48d1-a2f0-48d61ae00429",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Rationale for Treatment Switching",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "387ea1b6-31b8-4786-90a6-6ad6df5c1056",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "TKI = Tyrosine kinase inhibitors, HCP = Healthcare professional. References: HCP Qualitative & Quantitative Interviews (ClearView); Hochhaus A et al. ASH 2015; Hochhaus A et al. Leukemia. 2017; 31(7):1525-1531; Osorio S et al. Ann Hematol. 2018; 97(11):2089-2098; Rea et al. Blood. 2021; blood.2020009984; Baccarani M and Gale RP. Leukemia. 2021; 35:2199-2204; Icluig (ponatinib) USPI; Sprycel (dasatinib) USPI; Tasigna (nilotinib) USPI; Bosulif (bosutinib) USPI",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d48cce7-a124-4004-9410-125417805beb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Approximately 1 in 5 patients switch therapy within the first year and ~40% of patients switch in the first 5 years (1L & 2L). Growing 3L+ patient population (>25% of CP-CML) with limited treatment options. Except for asciminib, the approved TKIs have poor kinase selectivity resulting in tolerability issues that impact efficacy. Comorbidities, restrictions with concomitant medications, and specific administration requirements impede long-term patient adherence. Fewer than 10% of patients successfully achieve sustained treatment-free remission (TFR).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d516db2b-a451-48a7-9309-b42cf35b2780",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Significant Need Remains for More Treatment Options for CML",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf00da4e-cf3d-4288-9241-58525ec45612",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 9,
      "beatId": "f1c5daaa-0597-4f81-b694-1845468beefb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document identifies a significant need for better treatment options for chronic myeloid leukemia and other cancers.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 29,
      "from": 10,
      "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 29,
      "from": 20,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "cb84aefe-a7ad-46b2-afcc-84f44e849500",
      "evidence": "The document discusses the limitations and toxicity of current treatments for CML, highlighting the need for better options.",
      "position": 0,
      "objective": "What are the consequences of not having better treatment options for CML?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}